Table 2.
Characteristics of diagnosed CRLM in each round of surveillance
| Parameters | Round 1 | Round 2 | Round 3 |
|---|---|---|---|
| Pre-patient | |||
| Total number of diagnosed patients | 50 | 42 | 27 |
| Age (y) a | 57 (33-78) | 60.5 (30-77) | 54 (33-75) |
| Sex, female/male | 14 (28.0)/36 (72.0) | 16 (38.1)/26 (61.9) | 13 (48.1)/14 (51.9) |
| BMI b | 22.6 (4.5) | 21.9 (5.2) | 21.4 (3.8) |
| Fatty liver disease Y/N | 13 (26.0)/37 (74.0) | 12 (28.6)/30 (71.4) | 9 (33.3)/18 (74.1) |
| Number of CRLM | |||
| 1 | 21 (42.0) | 16 (38.1) | 9 (33.3) |
| >1, ≤5 | 24 (48.0) | 21 (50.0) | 14 (51.9) |
| >5, ≤10 | 5 (10.0) | 5 (11.9) | 4 (14.8) |
| Distribution | |||
| Unilobar | 27 (54.0) | 23 (54.8) | 16 (59.3) |
| Bilobar | 23 (46.0) | 19 (45.2) | 11 (40.7) |
| Days between NE-AMRI and CE-CT a | 2 (0-14) | 2 (0-8) | 3 (0-12) |
| Extrahepatic metastases Y/N | 10 (20.0)/40 (80.0) | 7 (16.7)/35 (83.3) | 6 (22.2)/21 (77.8) |
| Pre-lesion | |||
| Total number of lesions | 148 | 132 | 89 |
| Proof | |||
| Histopathology | 115 (77.7) | 95 (72.0) | 70 (78.7) |
| CE-MRI | 33 (22.3) | 37 (28.0) | 19 (21.3) |
| Tumor size | |||
| <10 mm | 42 (29.4) | 45 (34.1) | 29 (32.6) |
| 10–20 mm | 57 (38.5) | 52 (39.4) | 38 (42.7) |
| >20 mm | 49 (33.1) | 35 (26.5) | 22 (24.7) |
Y = yes, N = no. Unless otherwise specified, data are numbers of patients, with percentage in parentheses.
a
Data are medians, with ranges in parentheses.
b
Data are means, with standard deviations in parentheses. Calculated as weight in kilograms divided by height in meters squared.